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Abstract
Background: Liver biopsies in pediatric hematopoietic stem cell transplantation (HSCT) patients are as and effective
when performed at bedside in the Bone Marrow Transplant Unit (BMTU) than in the Day Surgery Unit (DSU), with
better patient compliance and lower emotional distress for these children.
Methods: The study group consisted of 45 children who underwent allogeneic HSCT. We reviewed 68 liver biopsies
performed between April 2006 and September 2015. 12 (17.6 %) biopsies were performed in the DSU and 56 (82.3 %)
in the BMTU; nine (13.2 %) prior to HSCT and 59 (86.7 %) after HSCT. Pre-procedural behavioral status (subjective score)
was evaluated by pediatric transplant physicians by filling in a questionnaire employing a three-point scale: “calm and
cooperative”, “agitated and non-cooperative” or “frightened and suffering”. Objective score was obtained measuring
patient’s heart rate before the procedure and comparing it with mean heart rate.
Results: Patients who underwent the procedure at the BMTU experienced less emotional distress than those who
underwent it in the DSU: 58.3 % of patients treated at the DSU were agitated as compared with 16.1 % of those
treated at the BMTU (p < 0.01). Among the 59 biopsies performed after HSCT, 41 (69.5 %) were taken from
symptomatic patients for a diagnostic purpose and 18 (30.5 %) in asymptomatic ones in order to rule out hepatic
GVHD. Among these 18 procedures, GVHD was diagnosed in 16 (88.9 %) cases. Minor complications occurred in about
17 % of procedures (12 biopsies), at a rate of 25 % for the DSU location compared with 16 % for the BMTU location.
Only two major complications were reported, one in the DSU and one in the BMTU.
Conclusion: Liver biopsy performed at bedside in HSCT patients does not carry a higher risk of adverse events than
the same procedure performed in the DSU and has lower emotional distress associated with better patient
compliance, thus contributing significantly to a higher standard of care.
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Background
Over recent years, allogeneic hematopoietic stem cell
transplantation (HSCT) has become an important tech-
nique for treating pediatric diseases, especially
hematological and oncological disorders and congenital
errors, including congenital immunodeficiency. Great
improvements in survival rates have been achieved
owing to better control of these diseases, introduction of
less aggressive conditioning regimens, better manage-
ment of graft versus host disease and infectious compli-
cations, and improvements in human leukocyte antigen
typing, which has made highly accurate selection of un-
related donors possible. Thus, the benefits of HSCT now
outweigh the associated risks.
However, despite the decrease in transplant-related
mortality, previously unknown and difficult to treat
complications are common and can result in suboptimal
management. One of the most significant of these com-
plications is liver dysfunction, which has been classified
by Forbes et al. by cause as follows: graft-versus-host
disease (GVHD), drug hepatotoxicity, viral hepatitis, sep-
sis, veno-occlusive disease, and disease recurrence. A
significant proportion of liver complications are still
classified as of undetermined cause [1].
Liver biopsy is currently the gold standard means of
identifying the nature of hepatic lesions. This invasive
procedure is commonly considered high risk for
pediatric recipients of allogeneic HSCT because of the
possibility of fatal complications such as massive bleed-
ing, gastric perforation, respiratory distress during
anesthesia, sepsis, hemothorax, and ascites caused by
hepatic failure [2, 3].
We herein report a small retrospective series of 45
pediatric patients with allogeneic hematopoietic stem
cell transplants who had undergone ultrasound-guided
liver biopsy (single or multiple) between April 2006 and
September 2015. Our hypotheses were that it is safer
and more effective to perform liver biopsies at the bed-
sides of such patients than in the Day Surgery Unit
(DSU) and that it is associated with better patient com-
pliance and less emotional stress for the child, thus con-
tributing significantly to a higher standard of care.
Methods
Patients
Medical records of all pediatric patients with allogeneic
hematopoietic stem cell transplants who had undergone
percutaneous ultrasound-guided liver biopsy between
April 2006 and September 2015 in the Bone Marrow
Transplant Unit (BMTU) or DSU of the Institute for
Maternal and Child Health, Institute for Scientific Re-
search, Burlo Garofolo, in Trieste, Italy were retrospect-
ively reviewed and analyzed. The Institutional Review
Board approved the study protocol (reference no. 1105/
2015). Written informed consent for biopsies had been
obtained from the parents of all subjects.
During the observation period, 68 percutaneous
ultrasound-guided liver biopsies were performed. From
April 2006 to April 2012, 12 biopsies (17.64 %) were per-
formed in the DSU, which is external to the BMTU;
these biopsies involved a duty radiologist and the entire
operating room team. From April 2012 to September
2015, 56 biopsies (82.5 %) were performed on 36 pa-
tients in a laminar air flow room in the BMTU; these bi-
opsies involved a pediatric team that included
pediatricians certified in Pediatric Advanced Life Sup-
port (PALS) and BMTU nurses certified in Pediatric
Basic Life Support.
The study group consisted of 45 children with allogen-
eic hematopoietic stem cell transplants. They were di-
vided into the following four age groups: infants, under
1 year; young children, from 1 to 5 years; children, from
6 to 10 years; and adolescents, from 10 to 18 years [4].
The following data were collected for each study pa-
tient: sex, body mass index, primary disease, condition-
ing regimen, type of donor, GVHD prophylaxis, number
of HSCTs, pre-transplant hepatopathy, magnetic reson-
ance imaging (MRI) quantification of hepatic iron stores
[5], liver function tests, and platelet count at the time of
liver biopsy. Baseline patient characteristics are listed in
Table 1.
Twenty-seven children (60.0 %) had acute leukemia,
ten myelodysplastic syndromes (22.2 %), six inherited
diseases (13.3 %), one a solid tumor (2.2 %), and one
hemoglobinopathy (2.2 %).
All medical records of biopsy procedures and the
post-biopsy observation period, including any treatment
for any complications, were examined. Additionally,
changes in management prompted by biopsy results
were extracted.
Pretransplant conditioning
Thirty-nine of the 45 patients had undergone myeloabla-
tive conditioning and the remaining six non-
myeloablative conditioning regimens. Recipients of hap-
loidentical or matched unrelated donors had also re-
ceived antithymocyte globulin.
GVHD prophylaxis was performed with calcineurin in-
hibitor associated to mycophenolate mofetil and pred-
nisone in the matched unrelated and haploidentical
donor group.
Percutaneous ultrasound-guided liver biopsy
The indications for biopsy were persistent or progressive
alteration noted at 2 weekly follow-up assessments of at
least one clinical or laboratory marker of liver impair-
ment or cholestasis, abnormal radiological findings, or
one or more lesions suggestive of hepatic parenchymal
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infection. Contraindications to biopsy were as follows:
severe ascites, refractory thrombocytopenia, failure to
correct coagulation defects with transfusions of plasma
or specific coagulation factors, and severe respiratory or
hemodynamic impairment.
All 45 patients had undergone percutaneous biopsies
under deep sedation (five or six Ramsay scale sedation
scores [6]). Sedation in the SDU was induced by midazo-
lam, propofol and fentanyl administration, while in the
BMTU by midazolam, ketamine and propofol. Both sed-
ation protocols are illustrated in Fig. 1. In the operating
room, induction and maintenance of anesthesia were
performed by anesthesiologists, in the BMTU by a
PALS-certified pediatrician. Additionally, all patients had
received prophylactic treatment with parenteral antifibri-
nolytic agent tranexamic acid during the 30 min before
the procedure. From April 2012 onwards, sedation was
administered by a resident pediatrician at the BMTU
Table 1 Baselines characteristics of the sample of the study
Baseline characteristics n° % DSU (%) BMTU (%)
Patient n° 45 100 7 (15.5) 38 (84.4)
Gender F 15 33.3 5 (16.3) 13 (86.7)
M 30 66.6 5 (16.7) 25 (83.3)
Age <1 years 2 15.5 15.5 1 (50.0) 1 (50.0)
1–5 years 15 24.4 2 (13.3) 13 (86.7)
6–10 years 13 28.8 1 (7.8) 12 (92.3)
10–18 years 15 31.1 3 (20.0) 12 (80.0)
Primary disease AL 27 60.0 4 (14.8) 23 (85.2)
Hemoglobinopathy 1 2.2 - 1 (100)
Inherited disease 6 13.3 1 (16.7) 5 (83.3)
MDS 10 22.2 2 (20.0) 8 (80.0)
Solid tumor 1 2.2 - 1 (100)
Number of HSCT 1 37 82.1 6 (16.3) 31 (83.7)
2 5 11.1 1 (20.0) 4 (80.0)
3 2 4.4 - 2 (100)
Type of Donor Haploidentical 6 13.3 4 (66.7) 2 (33.3)
Matched related 18 40.0 2 (11.1) 16 (88.9)
Matched unrelated 21 86.6 1 (4.8) 20 (95.2)
Conditioning regimen Myeloablative 39 86.6 7 (17.9) 32 (82.1)
RIC 6 13.3 - 6 (100)
Gilbert syndrome Yes 9 20.0 1 (11.1) 8 (88.9)
No 36 80.0 6 (16.6) 30 (83.3)
Pre transplant hepatopathy No 18 40.0 1 (5.5) 17 (94.4)
Acquired metabolic disorders 1 2.2 - 1 (100)
Drug Hepatotoxicity 1 2.2 - 1 (100)
Inherited metabolic disease 2 4.4 1 (50.0) 1 (50.0)
Iron overload 21 46.6 4 (19.0) 17 (80.9)
Viral hepatitis 2 4.4 1 (50.0) 1 (50.0)
MRI quantification LIC Patients undergoing MRI 42 93.3 4 (9.5) 38 (90.5)
Normal liver 4 9.5 - 4 (100)
Slight overload 16 38.0 - 16 (100)
Moderate overload 8 19.0 2 (25.0) 6 (75.0)
Major overload 14 33.3 2 (14.3) 12 (85.7)
Obesity (BMI >30) 6 13.3 2 (33.3) 4 (66.7)
DSU Day Surgery Unit, BMTU Bone Marrow Transplant Unit, F Female, M Male, AL Acute leukemia, MDS Myelodisplasic syndromes, RIC Reduced intensity
conditioning, MRI Magnetic resonance imaging, LIC Liver iron concentration, BMI Body mass index
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who had received 4 weeks of training in the operating
room and practiced sedation for a further month, during
which tutoring was given by a pediatric anesthesiologist
[7] and by the radiologist who had performed all the bi-
opsy procedures; this radiologist had extensive experi-
ence in pediatric interventional radiology.
All procedures were supported by sonography per-
formed by the interventional radiologist who performed
the biopsy. A mapping sonogram was used to identify
the best approach for hepatic biopsy (generally in the
10th intercostal space in the anterior axillary line) and to
ensure a safe needle pathway that minimized the risk of
accidental puncture of interposing bowel, gall bladder,
lung, right kidney, or intrahepatic vessels and ducts. A
MyLab™30 US machine (Esaote, Genova, Italy) with a
multiband frequency probe (2.5–6.6 MHz) without a bi-
opsy adaptor was used in all cases.
Needle size was determined by age and body mass
index. An Ester automatic core biopsy device (Biopsybell
SRL, Mirandola, Italy) with a 16- or 18- gauge 150-mm
needle with a drawing area of 20 mm was employed.
Twenty liver biopsies (29.4 %) were obtained with 16-
gauge, 46 (67.6 %) with 18-gauge, and two (2.9 %) with
20-gauge needles.
Immediately after the biopsy, a further sonography
was performed to check for possible bleeding or other
complications. In the absence of complications, all pa-
tients were observed for 8 h after liver biopsy in our
Transplant Unit, in which central monitoring is avail-
able. Sonography was usually performed the next day on
inpatients and the evening of the same day on outpa-
tients. Patients with acute hemorrhage were examined
promptly by sonography CT scan with contrast medium.
Complications were defined as adverse events that oc-
curred as a direct result of the procedure. These were
classified as minor (local bleeding evaluable by sonog-
raphy, local or radiating pain) or major: bleeding requir-
ing transfusion or intervention (Hb decrease > 2 g/dL in
the 8 h after the procedure), infection, perforation, unin-
tentional organ injury, postoperative complications dir-
ectly related to the administration of anesthesia, and
specific organ complications such as cholangitis and
pneumothorax [8].
Pre-procedural behavior status was evaluated by the
pediatric transplant physician of our BMTU, so that the
same person made the assessments during liver biopsy
in both the DSU and BMTU. To give this subjective
score, some minutes before every procedure the
pediatrician evaluates the patient’s behavior and asks
each patient a few questions to assess anxiety on a 3-
point scale: “calm and cooperative”, “agitated and non-
cooperative” or “frightened or suffering”. Adverse effects
of ketamine administration were reported as “frightened
or suffering”. Objective score was obtained measuring
patient’s heart rate immediately before administration of
anesthetic drugs and comparing it with mean heart rate.
The mean heart rate for each of four age groups was cal-
culated using the heart rates documented during entire
admission. Heart rate data was obtained by pulse oxim-
etry measurements in both locations (DSU and BMTU).
Tachycardia were defined as a 20 % increase above the
mean heart rate [9].
Statistical analysis
Statistical analysis was performed with IBM SPSS statis-
tical software v.20. Data are presented as means ± stand-
ard deviation. Comparisons between categorical
variables were evaluated with Fisher’s exact test. Com-
parison between numerically limited variables were eval-
uated with Wilcoxon test. A p-value of <0.05 was
considered statistically significant.
Results
The clinical and biological characteristics of the 45 pa-
tients categorized by their location are presented in
Table 1. The median time between HSCT and the biopsy
procedure was 156 days ± 141 (range 29–641 days) for
subjects who had biopsies taken after receiving their
transplants; additionally, biopsies were taken before the
HSCT in nine (20 %) cases. Of the 68 liver biopsies, 12
(17.6 %) were performed in the DSU and 56 (82.3 %) in
the BMTU; 31 (45.6 %) were performed on inpatients
and 37 (54.4 %) on outpatients. Suitable samples were
obtained in 98.5 % of procedures and microscopic exam-
ination of biopsy material revealed abnormalities in 66/
68 samples (97.0 %).
In general, platelet counts of more than 100 × 109/L
and international normalized ratio (INR) values lower
than two prior to the procedure are preferred. Pre-
Fig. 1 Sedation protocols categorized by location
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procedure platelet counts were >140 × 109/L in all pa-
tients, platelet transfusions having been administered
prior to the procedure in 29 cases. None of the HSCT
patients in the study had an INR greater than two (me-
dian INR 1.07 ± 0.16); three patients received fresh fro-
zen plasma transfusions before the procedure to reduce
their high risk of bleeding. The patients’ pre-procedural
liver function test results (mean ± standard deviation)
were: total bilirubin 0.79 ± 0.69 mg/dL; direct bilirubin
0.37 ± 0.41 mg/dL; alanine transferase 59.79 ± 56.47 U/L;
and alkaline phosphatase (ALP) 179.54 ± 100.4 U/L. As-
cites was observed in 5/of 68 procedures (7.35 %). Pre-
transplant hepatopathy had been present in 27 patients
(60.0 %), a high proportion being associated with iron
overload (46.6 %).
Nine (13.2 %) liver biopsies were performed prior to
the HSCT: four to define iron overload disease, one to
stage chronic hepatitis B disease, one to confirm the
healing of hepatitis C disease after treatment with sofos-
buvir and ribavirin, and two to diagnose hepatopathy of
uncertain origin.
Of the 59 liver biopsies (86.76 %) performed after
HSCT, 41 (69.49 %) were performed on symptomatic pa-
tients for diagnostic purposes and 18 (30.50 %) on
asymptomatic patients to determine whether hepatic
GVHD was present; 16 of these 18 patients (88.9 %)
were found to have GVHD.
In 36 liver biopsies (52.9 %), the pathological findings
led to changes in clinical management, either because a
new diagnosis was made or resolution or progression of
GVHD identified. The finding of resolution of GVHD
led to suspension of immunosuppressive treatment,
whereas confirmation of GVHD or evidence of progres-
sion of this condition prompted intensification of ther-
apy. In 32 hepatic samples (47.1 %) there were no
histological changes since the previous diagnosis, and
these patients’ therapy was therefore not modified
(Table 2).
The rate of biopsy procedures without complication
was 75 % in the DSU group and 83.9 % in the BMTU
group, and there was no significant difference between
the two groups. Minor complications, namely local
Table 2 Histological diagnosis and clinical management
Clinical characteristics N° (%) DSU (%) BMTU (%)
Total biopsy 68 (100) 12 (17.6) 56 (82.3)
Number of biopsy per patient 1 17 (37,7) 3 (17.6) 14 (82.3)
2 17 (37,7) 3 (17.6) 14 (82.3)
≥3 11 (24,4) 1 (9.1) 10 (90.9)
Histological diagnosis Drug Hepatotoxicity 2 (3,9) 1 (50.0) 1 (50.0)
AIH 1 (1,4) - 1 (100)
GVHD 24 (35,2) 4 (16,7) 20 (83.3)
GVHD + IO 19 (27,9) 3 16
GVHD + IO + Infection 1 (1,4) - 1 (100)
GVHD + IO + MD 2 (2,9) - 2 (100)
Infection 4 (5,8) 1 (25.0) 3 (75.0)
IO + Drug toxicity 4 (5,8) 1 (25.0) 3 (75.0)
IO + Infection 1 (1,4) 1 (100) -
IO + MD 1 (1,4) - 1 (100)
Iron overload 6 (8,8) 1 (16.7) 5 (83.3)
Metabolic Disorders 2 (2,9) 0 2 (100)
Normal 1 (1,4) 0 1 (100)
Changes in clinical management No 32 (47,1) 3 (9.4) 29 (90.6)
Yes 36 (52,9) 9 (25.0) 27 (75.0)
Outcome Improved 33 (48,5) 6 (18.2) 27 (81.8)
Recovered 13 (19,1) 2 (15.4) 11 (84.6)
Not changed 19 (27,9) 2 (10.5) 17 (89.5)
Worsened 1 (1,4) 1 (100) 0
Death 2 (2,9) 1 (50.0) 1 (50.0)
Histological diagnosis and clinical management. DSU Day surgery unit, BMTU Bone marrow transplant unit, AIH autoimmune hepatitis, GVHD Graft versus host
disease, IO Iron overload, MD Metabolic disease
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bleeding and pain at the site of the needle insertion, oc-
curred in about 17 % of procedures (12 biopsies): 3 pa-
tients (24.9 %) from the DSU group versus 9 patients
(16 %) from the BMTU group. Two major complications
were reported: one patient from DSU group had
hemorrhage requiring transfusion and one patient from
the BMTU had cholangitis requiring antibiotic treat-
ment. Moreover, medication, namely a single dose of an
opioid analgesic, was needed in only 9 % of all proce-
dures (six biopsies), with no significant difference be-
tween the two groups (Table 3).
As to behavioral status, patients were reported to be
“calm and cooperative” in approximately 80 % of pre-
procedure evaluations. This difference in incidence of
being calm and cooperative between the two procedure
locations was statistically significant (p < 0.01). Addition-
ally, 58 % of patients who had undergone biopsies in the
DSU were assessed as agitated or non-cooperative versus
16 % of those in the BMTU (also significant; p < 0.01)
(Table 3). The number of tachycardia events (objective
score) was signicantly higher in the DSU than in the
BMTU (58.3 % versus 16.1 %; P < 0.01). Unfortunately
the sample is very heterogenous, and many of the age
groups, especially in the DSU population, are to small
for statistical comparison. The pre-procedural heart
rates and the incidence of tachycardia events are re-
ported in the Table 4.
Discussion
Several small studies have suggested that liver biopsies
should be considered as risky in pediatric patients with
cancer or hematological disease [10] and that the mor-
bidity and mortality of this procedure is higher in chil-
dren than in adults [11, 12]. However, hepatopathy,
which has a morbidity rate of 80 % and mortality rate
close to 14 % in HSCT recipients, is a common compli-
cation in these patients [3]. Clinical and laboratory find-
ings are non-specific in many of these cases and
insufficient to make a definitive diagnosis.
Over the 3 years from April 2012 to September 2015,
57 liver biopsies were performed on 36 patients with
allogeneic hematopoietic stem cell transplants in our in-
stitution, which represents a more than 10-fold increase
in the biopsy rate. The main reason for this dramatic
jump is the increasing necessity of making histological-
based diagnoses because of the availability of targeted
therapies and the need to choose the optimal manage-
ment strategy. One consequence of increasing our liver
biopsy rate was that after April 2012, the only patient
who developed Grade 3–4 hepatic GVHD had developed
Grade 4 GVHD after receiving a donor lymphocyte infu-
sion for cryptosporidiosis.
MRI quantification of liver iron concentration had not
yet been introduced at the time our first two asymptom-
atic patients underwent liver biopsy to evaluate iron
overload. These two children’s main laboratory abnor-
malities were in ferritin and ALP concentrations. Exam-
ination of their biopsies confirmed hepatic iron overload
and showed a mild chronic GVHD. Because of the latter
unexpected finding, all subsequent patients with at least
one indicator of cholestasis (abnormally high concentra-
tions of ALP and/or bile acids) underwent liver biopsy
to determine whether subclinical GVHD was present.
This policy resulted in histological confirmation of
GVHD in 16 of 18 asymptomatic patients (88.89 %), the
management of all of whom was modified accordingly.
None of these patients showed any subsequent evidence
of GVHD.
There were only a few complications in our series.
Local bleeding and pain at the site of the needle
Table 3 Complications of biopsies performed in the DSU versus BMTU and behavioral status of patients: Evaluation of major and
minor complications after biopsy procedure and treatment adopted for complications; Pre-procedure behavioral status of the patient
is also reported
Complications and patient’s behavioral status DSU location BMTU location
No Complication 9 (75.0) 47 (83.9)
Minor complications Local bleeding 2 (16.6) 4 (7.1)
Local pain 1 (8.3) 5 (8.9)
Major Complications Bleeding requiring transfusion 1 (8.3) -
Infection - 1 (1,8)
Complication treatment None 9 (75.0) 47 (83.9)
Morphine 2 (16.6) 4 (7.1)
Surgical procedure or transfusion 1 (8.3) -
Tramadol - 5 (8.9)
Pre-procedure status Calm and cooperative 5 (41.7) 47 (84.0)
Agitated and non-cooperative 6 (50.0) 8 (14.3)
Frightened or suffering 1 (8.3) 1 (1.8)
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insertion occurred in about 17 % of procedures (12 biop-
sies). There were only two major complications (2.9 %):
a biliary tract infection and a hemothorax. The first bi-
opsy had been performed in the DSU and the second in
the BMTU. Both patients were in poor general condi-
tion, the former having Grade 4 GVHD and the latter
having undergone three transplants.
Our results confirm the usefulness of liver biopsy and
highlight that, in terms of complications, the procedure
is as safe as other procedures routinely performed on
such patients, such as lumbar puncture and bone mar-
row aspiration.
The change in location of the procedure from the
DSU to the BMTU has not altered its safety. On the
contrary, the rate of minor complications decreased
from 25 to 16 % after this change, which is likely not a
clinically significant difference considering how few pa-
tients had undergone the procedure in the DSU.
To date, little attention has been paid to the manage-
ment of the emotional stress that can be experienced by
young patients when they undergo invasive procedures
such as liver biopsies. All of the patients who are re-
ferred to the BMTU have undergone many diagnostic
and therapeutic procedures, some of which have been
invasive (such as bone marrow aspiration and lumbar
puncture). During their long stays in the BMTU, these
children develop close and trusting relationships with
the inpatient team. Our findings demonstrate that when
procedures are performed in the child’s room by a dedi-
cated pediatrician, an intervention radiologist, and mem-
bers of the day-to-day inpatient team, the patient is less
afraid or agitated [13]. Moreover, use of midazolam for
sedation reduces post-procedural anxiety because this
drug has been shown to enhance anterograde amnesia in
pediatric patients [14, 15].
When we analyzed the reports of behavioral status, we
noticed that 84 % of the BMTU population were reported
as being calm and collaborative prior to the procedure.
Moreover, when we compared the behavioral status and
the tachycardia events of patients treated in the DSU with
those at the BMTU, we observed higher emotional
distress with a higher incidence of tachycardia in those
treated at the DSU, more of whom were assessed as agi-
tated and non-cooperative. Indeed, 58.3 % of patients who
underwent biopsies in the DSU were agitated or non-
cooperative versus 16.1 % of those in the BMTU. Thus,
our patients who underwent the procedure in their own
rooms experienced less emotional distress than those who
underwent it in the less familiar and friendly environment
of the DSU, an important consideration for children.
Conclusions
In this small study, we found that liver biopsy is safe in
pediatric patients who have undergone HSCT, few com-
plications having been encountered. Moreover, our study
shows that biopsies performed in the patient’s room can
have the same outcomes as those performed in the DSU
but are associated with better patient compliance and
less emotional stress for the child, thus contributing sig-
nificantly to a higher standard of care.
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